This pilot study looked at vericiguat in patients with heart failure with reduced ejection fraction. The researchers measured blood vessel function and other markers over 12 weeks. Only 26 participants took part, with 25 finishing the full follow-up period. The trial was randomized, double-blind, and placebo-controlled.
The main finding involved a specific blood pressure marker called NT-proBNP. Patients taking vericiguat showed a small reduction in this marker compared to those taking a placebo. However, the study did not find significant differences in blood vessel dilation, inflammation, exercise capacity, or quality of life. No serious safety issues were reported during the short trial.
The study size was very small. Because of this, the results lack the precision needed to confirm a real treatment effect. The authors note that larger and longer studies are needed to properly evaluate the drug. This early evidence suggests potential but requires more data before changing medical practice. Readers should wait for bigger trials before drawing firm conclusions.